Athersys Company Profile
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
As represented by its name, (Athersys - derived from advanced therapeutic systems), the Company is committed to developing novel therapeutic products that deliver substantial improvements over existing therapies through the application and utilization of its advanced, proprietary technology platforms.
Through internal development and acquisition of key technologies, Athersys has established a unique blend of competencies in areas such as molecular biology, cell biology, genomics, protein biochemistry, medicinal chemistry, and pharmacology. The Company has fully integrated pre-clinical drug discovery and development capabilities, and is focused on advancing a portfolio of therapeutic development programs into the clinic.
3201 Carnegie Avenue
United States of America
Email: email@example.com., firstname.lastname@example.org
The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, says it is working with US stem-cell specialist Athersys on m...
By Wall Street Titan:On April 28, 2014 Athersys (ATHX) reported the preliminary results of its Phase II Clinical Trial in Ulcerative Colitis. The double blinded, placebo controlled study is being fina...
Call Start: 16:30 Call End: 17:32 Athersys, Inc. (ATHX) Q1 2014 Earnings Conference Call May 8, 2014 4:30 PM ET Executives Amy Raskopf - IR B.J. Lehmann - President and COO Gil Van Bokkelen - Chai...
Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke pati...
Athersys, Inc. (NASDAQ:ATHX) Q2 2014 Earnings Conference Call August 11, 2014, 04:30 PM ET Executives Lisa Wilson - Investor Relations, In-Site Communications Gil Van Bokkelen - Chairman and Chief...
April 28 (Reuters) - Athersys Inc said its experimental stem-cell therapy for treating an inflammatory bowel disease failed to show any benefit in patients in a mid-stage trial.
US biotech firm Athersys has announced that interim results from the Phase II clinical study of its MultiStem cell therapy show that it fails to demonstrate meaningful benefit in treating refractory u...
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate...
Drugs and Medications
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.As represented by its name, (Ather...
Athersys is a biotechnology company engaged in the research and development of products for the treatment and diagnosis of genetic and immunologic disorders. The company has a core expertise in the f...
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company ...
More Information about "Athersys" on BioPortfolio
We have published hundreds of Athersys news stories on BioPortfolio along with dozens of Athersys Clinical Trials and PubMed Articles about Athersys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athersys Companies in our database. You can also find out about relevant Athersys Drugs and Medications on this site too.